Bedside activated partial thromboplastin time monitoring: Just a matter of time?

American Heart Journal

Volumn 137, Issue 1, 1999, Pages 8-11

  Patel, V B ^a   Moliterno, D J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; EDITORIAL; FIBRINOLYTIC THERAPY; HUMAN; PRIORITY JOURNAL; THROMBOPLASTIN TIME; UNSTABLE ANGINA PECTORIS;

EID: 0032910102     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70454-0     Document Type: Editorial

References (16)

1. AM Telford C. Wilson Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome Lancet I 1981 1225 1228
2. P Théroux H Quimet J McCans Aspirin, heparin, or both to treat acute unstable angina N Engl J Med 17 1988 1105 1111
3. CB Granger J Hirsh RM Califf Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO trial Circulation 93 1996 870 888
4. GUSTO IIa Investigators Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes Circulation 90 1994 1631 1637
5. GUSTO IIb Investigators A comparison of recombinant hirudin with heparin for treatment of acute coronary syndromes N Engl J Med 335 1996 775 782
6. EM. Antman Hirudin in acute myocardial infarction. Safety report from the thrombolysis and Thrombin Inhibition in Myocardial Infarction trial (TIMI) 9A trial Circulation 90 1994 1624 1630
7. EM. Antman Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial Circulation 94 1996 911 921
8. EPILOG Investigators Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abciximab with lower heparin dosages on ischemic complications of percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
9. CP Cannon CH McCabe TD Henry A pilot trial of recombinant desulfatohirudin compared with heprain in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial J Am Coll Cardiol 23 1994 993 1003
10. J Ansell C Tiarks J Hirsh Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. A new method for monitoring heparin therapy Am J Clin Pathol 95 1991 222 227
11. GJ Despotis CW Hogue Jr SA Santoro Effect of heparin on whole blood activated partial thromboplastin time using a portable, whole blood coagulation monitor Crit Care Med 23 1995 1674 1679
12. GJ Despotis SA Santoro E Spitznagel Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation J Thorac Cardiovasc Surg 107 1994 271 279
13. ES McErlean SA DeLuca K Brown Point of care testing for aPTT improves cost outcomes following coronary intervention J Am Coll Cardiol 31 suppl A 1998 49A [abstract]
14. RC Becker SP Ball P Eisenberg A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease Am Heart J 136 1998 59 71
15. K Newby RA Harrington M Bhapkar Tight control of aPTT in acute coronary syndrome patients using an automated strategy for bedside heparin adjustment: Results from the PARAGON A trial Circulation suppl I 1997 I-748
16. PARAGON Investigators A randomized trial of potent platelet IIb/IIIa antagonism, heparin, or both in patients with unstable angina: the PARAGON study Circulation 97 24 1998 2386 2395